Zentalis Earnings Reports

Zentalis Pharmaceuticals reported a net loss of $48.3 million for the first quarter of 2025, a significant decrease from the net income of $10.1 million in the same period last year, primarily due to the absence of license revenue and higher operating expenses including restructuring costs. The company ended the quarter with $332.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2027. Key operational progress included the first patient dosed in Part 2a of the Phase 2 DENALI clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer.

Zentalis Pharmaceuticals reported its Q2 2024 financial results, with a cash, cash equivalents, and marketable securities position of $426.4 million as of June 30, 2024. The company believes its existing cash will fund operations into mid-2026. R&D expenses were $48.4 million, and G&A expenses were $16.8 million.

Zentalis Pharmaceuticals reported its Q1 2024 financial results, highlighting a cash, cash equivalents, and marketable securities position of $489.0 million. The company anticipates a catalyst-rich period in the second half of 2024 and into 2025, focusing on the clinical profile of azenosertib.

Zentalis Pharmaceuticals reported a cash balance of $483 million as of December 31, 2023, projecting a cash runway into 2026. The company is advancing its azenosertib clinical development program and anticipates multiple clinical data readouts in 2024 and 2025, with plans to submit its first NDA in 2026. They also strengthened their management team with key appointments.

Zentalis Pharmaceuticals reported a cash balance of $516.6 million as of September 30, 2023, projecting a cash runway into 2026. The company is focused on advancing azenosertib, with plans to submit the first NDA in a gynecologic malignancy in 2026. Updated data from the azenosertib monotherapy study showed a 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients.

Zentalis Pharmaceuticals reported strong azenosertib data and a solid cash position after raising approximately $250.0 million in gross proceeds from a recent follow-on offering, extending cash runway into 2026. Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients. The company is well positioned to advance its program with its current cash reserves.

Zentalis Pharmaceuticals reported a cash balance of $392 million as of March 31, 2023, with a projected cash runway into the second quarter of 2025. The company is on track to disclose monotherapy dose and updates on accruing trials for azenosertib in 1H 2023 and will present positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer at ASCO.

Zentalis Pharmaceuticals reported a cash balance of $437.4 million as of December 31, 2022, projecting a cash runway into Q2 2025. The company is focused on advancing its clinical development strategy for azenosertib and ZN-d5.

Zentalis Pharmaceuticals reported a cash balance of $422 million as of September 30, 2022, with a projected cash runway into 2025. The company is advancing its clinical strategy for ZN-c3, including dose optimization and expansion into Cyclin E driven high-grade serous ovarian cancer. Collaborations with Pfizer and GSK are ongoing to explore ZN-c3 in combination therapies.

Zentalis Pharmaceuticals reported its Q2 2022 financial results, highlighting the strengthening of its leadership team, a $25 million equity investment from Pfizer, and approximately $200.2 million in gross proceeds from a recent follow-on offering, extending the company's cash runway into 2025. The company is focusing on advancing its lead clinical candidates, ZN-c3 and ZN-d5, while discontinuing the development of ZN-c5 and ZN-e4.

Zentalis Pharmaceuticals reported its first quarter 2022 financial results, highlighting clinical milestones and strategic partnerships, including initial data on ZN-c3 and a $25 million equity investment from Pfizer. Cash runway extended into Q1 2024.

Zentalis Pharmaceuticals reported its Q4 and full year 2021 financial results, with a cash, cash equivalents, and marketable securities position of $339.9 million as of December 31, 2021. Research and development expenses for the year ended December 31, 2021 were $175.6 million, and general and administrative expenses were $40.9 million.

Zentalis Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma and the ongoing enrollment in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC). The company's cash, cash equivalents, and marketable securities totaled $366.8 million as of September 30, 2021.

Zentalis Pharmaceuticals reported financial results for the second quarter ended June 30, 2021. The company raised approximately $173 million in gross proceeds from a recent follow-on offering and had significant clinical and regulatory advances.

Zentalis Pharmaceuticals reported a net loss of $50.4 million for the first quarter ended March 31, 2021. The company highlighted the clinical development of ZN-c3, with strong data presented at AACR, and announced a clinical collaboration with GlaxoSmithKline (GSK) to evaluate ZN-c3 in combination with niraparib. As of March 31, 2021, Zentalis had cash, cash equivalents and marketable securities of $298.4 million.

Zentalis Pharmaceuticals reported a net loss of $40.4 million for the fourth quarter of 2020, compared to a net loss of $14.5 million for the same period in 2019. As of December 31, 2020, the company had cash, cash equivalents, and marketable securities of $338.5 million.

Zentalis Pharmaceuticals reported a net loss of $34.7 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $367.4 million as of September 30, 2020. The company made progress in its oncology pipeline, including ZN-c5 and ZN-c3, and entered a collaboration with Eli Lilly.

Zentalis Pharmaceuticals reported a net loss of $27.3 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $233.2 million as of June 30, 2020, which, along with proceeds from a follow-on offering, is expected to fund operations into 2023. The company also completed its IPO, raised additional capital, and entered into strategic collaborations.

Zentalis Pharmaceuticals reported a net loss of $16.2 million for Q1 2020, compared to a net loss of $8.7 million for the same period in 2019. The company's cash and cash equivalents were $63.7 million as of March 31, 2020. They completed an initial public offering, raising approximately $190.0 million in gross proceeds.